Latest news with #AcuteMyocardialInfarction
The Hindu
25-07-2025
- Health
- The Hindu
Covid vaccination had no effect on risk of heart attacks: Health Minister Nadda tells Lok Sabha
Union Health Minister J. P. Nadda said on Friday (July 25, 2025) Covid vaccination had no effect on the risk of heart attacks. In a written response to a question in Lok Sabha, he also clarified that data regarding heart attack cases is not maintained centrally. Heart attack cases are not notifiable and there is no central registry for these. The Indian Council of Medical Research (ICMR) has informed that in order to understand the reasons for heart attack, ICMR-National Institute of Epidemiology (ICMR-NIE) conducted a multi-centric matched case-control study in 25 hospitals across India. Cases were patients aged 18-45 years admitted in the study hospitals with newly diagnosed Acute Myocardial Infarction (AMI) between October 2021 and January 2023, Mr. Nadda said. Controls were patients aged 18-45 years admitted in the same hospital for other causes, matched for time of hospitalisation. Information was collected regarding the various risk factors. Sharing the key findings of the study (not yet published), Mr. Nadda said that hospitalisation with AMI was associated with presence of any known co-morbidity, family history of thrombotic event and ever being smoker. Receipt of vaccination against COVID-19 had no effect on the risk of AMI. Even in those without any comorbidities, family history of thrombotic events and ever smoking was associated with increased risk of AMI; he said. He further informed that the ICMR in last two years has funded two centres of advanced research for research on cardiac disorders. The National Health Mission (NHM) provides technical and financial support to the states and Union territories under the National Programme for Prevention and Control of Non-Communicable Diseases (NP-NCD), Mr. Nadda said. Cardiovascular disease is an integral part of NP-NCD. Under the programme, 770 district NCD clinics, 6410 community health centres NCD clinics and 233 cardiac care units have been set up. Further, a population-based initiative for prevention, control and screening for common NCDs including diabetes and hypertension has been rolled out in the country under NHM as a part of comprehensive primary health care. Under the initiative, people above 30 years of age are targeted for their screening, Mr. Nadda said.
Globe and Mail
16-05-2025
- Business
- Globe and Mail
Acute Myocardial Infarction Market to Evolve with Novel Therapies and Strategic Advancements by 2034
The Acute Myocardial Infarction (AMI) market is undergoing transformative change, spurred by advancements in rapid diagnostic technologies, personalized treatment approaches, and cardioprotective therapeutics. DelveInsight's latest AMI market report explores epidemiological trends and current treatment practices, along with pipeline innovations aimed at reducing infarct size and improving long-term cardiovascular outcomes. The ' Acute Myocardial Infarction Market Report ' by DelveInsight offers a robust analysis of market size, treatment algorithms, and unmet needs across the 7MM, providing stakeholders with actionable insights to navigate a highly competitive and evolving cardiovascular space. Some of the Key Facts of the Acute Myocardial Infarction Market Report: • The AMI market in the 7MM is valued at USD 1.6 billion in 2023, with expected strong growth. • In 2023, the U.S. had ~823K incident AMI cases, projected to rise by 2034. • LODOCO, FDA-approved by AGEPHA Pharma, is the first treatment targeting residual inflammatory risk in cardiovascular disease. • NSTEMI cases (~607K) outnumbered STEMI cases in the U.S. in 2023. • In March 2025, Powerful Medical, a leader in AI-driven cardiovascular diagnostics, announced that its PMcardio STEMI AI ECG model has received Breakthrough Device Designation from the FDA. This recognition highlights PMcardio's innovation in detecting ST-elevation myocardial infarction (STEMI) and STEMI equivalents, conditions that require urgent intervention. • In September 2024, GE HealthCare (Nasdaq: GEHC) announced FDA approval of FLYRCADO (flurpiridaz F 18), the first positron emission tomography myocardial perfusion imaging (PET MPI) agent for detecting coronary artery disease (CAD). Flyrcado offers superior diagnostic efficacy compared to the widely used single-photon emission computed tomography (SPECT) MPI, enhancing access to PET MPI and improving accuracy, particularly in challenging cases like high BMI patients and women. • Emerging acute myocardial infarction drugs include Selatogrel, Dutogliptin, Olpasiran, FDY-5301, Ziltivekimab, Milvexian, Zalunfiban, KAND567, ProtheraCytes, and others. • Leading companies in the acute myocardial infarction market include Idorsia Pharmaceuticals, Viatris, AstraZeneca, Boehringer Ingelheim and Eli Lilly and Company, Amgen and Arrowhead Pharmaceuticals, Idorsia Pharmaceuticals, Faraday Pharmaceuticals, Novo Nordisk, Bristol Myers Squibb and Johnson & Johnson Innovative Medicine, Recardio, CeleCor Therapeutics, Kancera, CellProthera and BioCardia, Mesoblast, Boehringer Ingelheim, and others. To know in detail about the acute myocardial infarction market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: Acute Myocardial Infarction Market Forecast Acute Myocardial Infarction Overview Acute Myocardial Infarction (AMI) refers to the death of heart muscle tissue due to the sudden blockage of a coronary artery. Common symptoms include chest pain, shortness of breath, nausea, and sweating. Diagnosis is based on electrocardiogram (ECG) findings and cardiac biomarkers. Treatment typically involves antiplatelet and anticoagulant medications, nitrates, beta-blockers, statins, and timely reperfusion therapies. In ST-segment elevation myocardial infarction (STEMI), emergency reperfusion is achieved through fibrinolytics, percutaneous coronary intervention (PCI), or coronary artery bypass grafting (CABG). In non-ST-segment elevation myocardial infarction (NSTEMI), PCI or CABG is also used. AMI remains a leading cause of mortality in developed nations and is classified into two main types: STEMI and NSTEMI. While unstable angina shares similarities with NSTEMI, it does not show elevated cardiac biomarkers. Get a free sample of the acute myocardial infarction market report with key insights and emerging therapies here: Acute Myocardial Infarction Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Acute Myocardial Infarction Epidemiology Segmentation: The Acute Myocardial Infarction epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by: • Total Incident Cases of AMI • Type-Specific Incident Cases of AMI • Gender-Specific Incident Cases of AMI Download the report to understand which factors are driving acute myocardial infarction epidemiology trends @ Acute Myocardial Infarction Epidemiology Forecast Acute Myocardial Infarction Drugs Uptake, and Pipeline Development Activities The acute myocardial infarction drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the acute myocardial infarction market or expected to be launched during the study period. The analysis covers the acute myocardial infarction market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the acute myocardial infarction pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Acute Myocardial Infarction Market Strengths • Strong pipeline with innovative therapies targeting inflammation, thrombosis, and cardiac repair. • High disease burden and awareness ensure steady demand for treatment and care. Acute Myocardial Infarction Market Weaknesses • High treatment costs limit access in low- and middle-income regions. • Delayed diagnosis and limited emergency care affect outcomes in underserved areas. Scope of the Acute Myocardial Infarction Market Report • Study Period: 2020–2034 • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] • Key Acute Myocardial Infarction Therapies: Selatogrel, Dutogliptin, Olpasiran, FDY-5301, Ziltivekimab, Milvexian, Zalunfiban, KAND567, ProtheraCytes, and others. • Key Acute Myocardial Infarction Companies: Pharmaceuticals, Viatris, AstraZeneca, Boehringer Ingelheim and Eli Lilly and Company, Amgen and Arrowhead Pharmaceuticals, Idorsia Pharmaceuticals, Faraday Pharmaceuticals, Novo Nordisk, Bristol Myers Squibb and Johnson & Johnson Innovative Medicine, Recardio, CeleCor Therapeutics, Kancera, CellProthera and BioCardia, Mesoblast, Boehringer Ingelheim, and others. • Acute Myocardial Infarction Therapeutic Assessment: Acute myocardial infarction, currently marketed, and acute myocardial infarction emerging therapies • Acute Myocardial Infarction Market Dynamics: Acute myocardial infarction market drivers and Acute Myocardial Infarction market barriers • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies • Acute Myocardial Infarction Unmet Needs, KOL's views, Analyst's views, Acute Myocardial Infarction Market Access and Reimbursement To learn more about the key players and advancements in the acute myocardial infarction treatment landscape, visit the Acute Myocardial Infarction Market Analysis Report Table of Contents 1. Acute Myocardial Infarction Market Report Introduction 2. Executive Summary for Acute Myocardial Infarction 3. SWOT analysis of Acute Myocardial Infarction 4. Acute Myocardial Infarction Patient Share (%) Overview at a Glance 5. Acute Myocardial Infarction Market Overview at a Glance 6. Acute Myocardial Infarction Disease Background and Overview 7. Acute Myocardial Infarction Epidemiology and Patient Population 8. Country-Specific Patient Population of Acute Myocardial Infarction 9. Acute Myocardial Infarction Current Treatment and Medical Practices 10. Acute Myocardial Infarction Unmet Needs 11. Acute Myocardial Infarction Emerging Therapies 12. Acute Myocardial Infarction Market Outlook 13. Country-Wise Acute Myocardial Infarction Market Analysis (2020–2034) 14. Acute Myocardial Infarction Market Access and Reimbursement of Therapies 15. Acute Myocardial Infarction Market Drivers 16. Acute Myocardial Infarction Market Barriers 17. Acute Myocardial Infarction Appendix 18. Acute Myocardial Infarction Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefit from market analysis to accelerate business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Jatin Vimal Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
